ES2196155T3 - Pprocedimientos para inducir la produccion de anticuerpos contra las bacterias de la familia cs4-cfa/1 de e. coli. - Google Patents

Pprocedimientos para inducir la produccion de anticuerpos contra las bacterias de la familia cs4-cfa/1 de e. coli.

Info

Publication number
ES2196155T3
ES2196155T3 ES96918041T ES96918041T ES2196155T3 ES 2196155 T3 ES2196155 T3 ES 2196155T3 ES 96918041 T ES96918041 T ES 96918041T ES 96918041 T ES96918041 T ES 96918041T ES 2196155 T3 ES2196155 T3 ES 2196155T3
Authority
ES
Spain
Prior art keywords
peptide
formula
cfa
coli
consensus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96918041T
Other languages
English (en)
Inventor
Frederick Cassels
Jeffrey Anderson
John Mark Carter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United States Department of the Army
Original Assignee
United States Department of the Army
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United States Department of the Army filed Critical United States Department of the Army
Application granted granted Critical
Publication of ES2196155T3 publication Critical patent/ES2196155T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1228—Enterobacterales (O), e.g. Citrobacter (G), Serratia (G), Proteus (G), Providencia (G), Morganella (G) or Yersinia (G)
    • C07K16/1232—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

UN PEPTIDO CONSENSO DE 36 AMINOACIDOS HA SIDO DISEÑADO PARA ACTUAR COMO UN INMUNOGENO PARA LA OBTENCION DE ANTICUERPOS CONTRA LAS PROTEINAS DE TODOS LOS MIEMBROS DE LA FAMILIA DE E. COLI CS4 DENTIDAD, EL RESTO DE LA SECUENCIA DE LAS PROTEINAS MUESTRA MUCHA MENOS HOMOLOGIA ENTRE LAS CEPAS. LA REGION DE LA PROTEINA REPRESENTADA EN LA SUBUNIDAD COMPRENDE EPITOPOS CONOCIDOS LINEALES DE CELULAS B Y T DE CFA/1. EL PEPTIDO CONSENSO POSEE UN ELEVADO GRADO DE HOMOLOGIA CON CEPAS PORTADORAS DE SEIS DIFERENTES FACTORES DE COLONIZACION. EL PEPTIDO CONSENSO TIENE LA FORMULA: **FORMULA**. UN PEPTIDO ALTERNATIVO, IDENTIFICADO COMO EL PEPTIDO CONSENSO 2 TIENE LA FORMULA: **FORMULA**.
ES96918041T 1995-06-02 1996-06-03 Pprocedimientos para inducir la produccion de anticuerpos contra las bacterias de la familia cs4-cfa/1 de e. coli. Expired - Lifetime ES2196155T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/460,617 US5914114A (en) 1995-06-02 1995-06-02 Method of raising antibodies against E. coli of the family CS4-CFA/I

Publications (1)

Publication Number Publication Date
ES2196155T3 true ES2196155T3 (es) 2003-12-16

Family

ID=23829417

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96918041T Expired - Lifetime ES2196155T3 (es) 1995-06-02 1996-06-03 Pprocedimientos para inducir la produccion de anticuerpos contra las bacterias de la familia cs4-cfa/1 de e. coli.

Country Status (8)

Country Link
US (1) US5914114A (es)
EP (1) EP0831900B1 (es)
AT (1) ATE235916T1 (es)
CA (1) CA2223013C (es)
DE (1) DE69627150T2 (es)
DK (1) DK0831900T3 (es)
ES (1) ES2196155T3 (es)
WO (1) WO1996038171A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6942861B2 (en) * 1996-04-19 2005-09-13 Henry M. Jackson Foundation For The Advancement Of Military Medicine Histidine-tagged intimin and methods of using intimin to stimulate an immune response and as an antigen carrier with targeting capability
US7404961B2 (en) * 1996-08-02 2008-07-29 The United States Of America As Represented By The Secretary Of The Army Peptides responsive to antibodies against consensus peptide of the CS4-CFA/I family proteins
DE69731312T2 (de) * 1996-08-02 2005-05-04 Department Of The Army, U.S. Government U.S. Army Medical Research & Materiel Command, Elizabeth Arwine Peptide spezifisch für antikörper gegen peptidconsensussequenzen aus der cs4-cfa/i-proteinfamilie
US7094883B1 (en) * 1996-08-02 2006-08-22 The United States Of America As Represented By The Secretary Of The Army Monoclonal antibody which agglutinates E. coli having the CS4-CFA/I family protein
DE69737233D1 (de) * 1996-08-02 2007-02-22 Us Army Monoklonaler antikörper für die agglutinierung von e. coli, das ein protein der cs4/cfa-familie enthält
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US6797276B1 (en) 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
US20060002959A1 (en) * 1996-11-14 2006-01-05 Government Of The United States Skin-sctive adjuvants for transcutaneous immuization
US20060002949A1 (en) 1996-11-14 2006-01-05 Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. Transcutaneous immunization without heterologous adjuvant
US7422747B2 (en) * 1997-10-07 2008-09-09 Loma Linda University Transgenic plant-based vaccines
US20040258703A1 (en) * 1997-11-14 2004-12-23 The Government Of The Us, As Represented By The Secretary Of The Army Skin-active adjuvants for transcutaneous immunization
AU4188100A (en) * 1999-04-08 2000-11-14 Gregory M. Glenn Dry formulation for transcutaneous immunization
JP2003505044A (ja) * 1999-07-15 2003-02-12 メディミューン，インコーポレーテッド ＦｉｍＡピリ線毛ベイストワクチン
AU7304000A (en) * 1999-09-22 2001-04-24 Isis Innovation Limited Virulence gene and protein, and their use
MXPA02010407A (es) 2000-04-20 2003-05-23 Univ Maryland Aislamiento y caracterizacion del operante csa (etec-cs4-pili) y metodos para su uso.
IES20010042A2 (en) * 2001-01-19 2002-12-11 Enfer Technology Ltd Test for transmissible spongiform encephalopathies
CA2437899C (en) * 2001-02-13 2012-05-15 Gregory M. Glenn Vaccine for transcutaneous immunization against etec-caused traveler's diarrhea
CA2477273A1 (en) * 2002-02-25 2003-09-18 U.S. Army Medical Research And Materiel Command Method of making cs6 antigen vaccine for treating, preventing, or inhibiting enterotoxigenic escherichia coli infections
AU2006249992B2 (en) * 2005-05-24 2010-09-02 The United States Of America As Represented By The Secretary Of The Navy Anti-adhesin based passive immunoprophylactic

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4411888A (en) * 1981-06-22 1983-10-25 The University Of Rochester Composition of a novel immunogen for protection against diarrheal disease caused by enterotoxigenic Escherichia coli
US4443549A (en) * 1981-10-19 1984-04-17 Molecular Genetics, Inc. Production of monoclonal antibodies against bacterial adhesins
US4971794A (en) * 1982-09-02 1990-11-20 Unilever Patent Holdings B.V. Production of antibodies using a mixture of strains of E. coli collectively expressing type I pili, CFA I pili, CFA II pili and K88 pili
US5417986A (en) * 1984-03-16 1995-05-23 The United States Of America As Represented By The Secretary Of The Army Vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres
US5017372A (en) * 1986-04-14 1991-05-21 Medicis Corporation Method of producing antibody-fortified dry whey
ES2042718T3 (es) * 1987-10-26 1993-12-16 Akzo Nv Procedimiento para la preparacion de una vacuna para proteger aves de corral contra septicemia producida por e. coli.
US5071977A (en) * 1989-05-10 1991-12-10 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Plaque inhibiting oligosaccharide
US5190746A (en) * 1989-05-10 1993-03-02 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Plaque inhibiting oligosaccharide
AU8417191A (en) * 1990-07-24 1992-02-18 Emory University Production of and compositions for the major cs1 pilin antigen including vaccines and diagnostic probes
US5698416A (en) * 1995-06-02 1997-12-16 The United States Of America As Represented By The Secretary Of The Army Methods for production of antigens under control of temperature-regulated promotors in enteric bacteria
US5637576A (en) * 1995-06-05 1997-06-10 Synsorb Biotech, Inc. Treatment of traveller's diarrhea
US5627163A (en) * 1995-06-05 1997-05-06 Synsorb Biotech, Inc. Treatment of traveller's diarrhea

Also Published As

Publication number Publication date
EP0831900A4 (en) 1999-01-20
EP0831900A1 (en) 1998-04-01
DK0831900T3 (da) 2003-07-21
US5914114A (en) 1999-06-22
CA2223013C (en) 2011-03-22
EP0831900B1 (en) 2003-04-02
WO1996038171A1 (en) 1996-12-05
DE69627150D1 (de) 2003-05-08
CA2223013A1 (en) 1996-12-05
DE69627150T2 (de) 2004-01-29
ATE235916T1 (de) 2003-04-15

Similar Documents

Publication Publication Date Title
ES2196155T3 (es) Pprocedimientos para inducir la produccion de anticuerpos contra las bacterias de la familia cs4-cfa/1 de e. coli.
NO872988D0 (no) Pattedyr-interleukin-4.
NO2017027I2 (no) efmoroctocog alfa eller et biotilsvarende legemiddel ihht Artikkel 10(4) av Directive 2001/83/EC, som beskyttet av basispatentet.
CY1113218T1 (el) Υβριδιο και διμερης εκφραση πρωτεϊνων ναϊσσεριας
ATE372376T1 (de) Kulturmedium mit sojabohnenextrakt als aminosäuren-quelle und ohne proteinkomplexe tierischen ursprungs
ES2151607T3 (es) Factor 12 de crecimiento y de diferenciacion.
DK0643974T3 (da) Vaccine mod Lyme-sygdom
ES8705467A1 (es) Un procedimiento para producir la proteina apoacuorina
ATE112687T1 (de) Mutanten des hiv-1 hüllproteins mit fehlenden hypervariabelen domänen.
ATE321859T1 (de) B2microglobulin fusionsproteine und varianten mit hoher affinität
BR9711457A (pt) Compostos e processo para o tratamento e diagnóstico de infecções micobacterianas.
PE20010694A1 (es) Plasmido autonomamente reproducible en bacterias corineformes
ATE41034T1 (de) Herstellung von protein a.
FR2662698B1 (es)
SE8801701D0 (sv) Production technology based on enzymic method
PT83972B (pt) Processo para a preparacao de proteina gm-csf e de seus derivados
ES2059436T3 (es) Proteina de la membrana exterior f de pseudomonas aeruginosa.
ES2058479T3 (es) Compuestos peptidicos.
DE59610251D1 (de) Konjugat, umfassend einen wirkstoff, ein polypeptid und einen polyether
DK0646176T3 (da) Levering og ekspression af et hybridoverfladeprotein på overfladen af grampositive bakterier
DE69125381D1 (de) Proteinstruktur des pflanzlichen toxins gelonin
AR014647A1 (es) Un polipeptido lipl32 de proteina de membrana externa leptoespiral, un polinucleotido aislado, un vector de expresion, una celula huesped, un metodopara producir dicho polipeptido lipl32, uso de dicho polipeptido para la manufactura de un medicamento, un anticuerpo, una composicion farmaceutica,
ATE25708T1 (de) Biologisch aktive konjugate, ihre herstellung und ihre anwendung.
ES2090365T3 (es) Un procedimiento para la produccion de proteinas hidrolizadas.
TR200401875T2 (tr) Endoparazit öldürücü bileşimler